Today’s AI Top Pick: PODD

8/5/2026 · Recently Alerted Turnaround screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · PODD84%361 resolved forecasts · 45d window · verify →

View the live PODD price forecast →

Today's pick · Recently Alerted TurnaroundPODDBUY NOW9.1 / 108/5/2026

PODD is the cleanest setup on this list: fundamentals are top-tier (fundamental_score 8, PEG 0.78, fwdPE 20.71 against 31.93% sales growth and 24.25% next-year EPS growth, 23% ROE, 10.44% profit margin, recom 1.54, targetUpsidePct 39.3%), and the tape is aligned with the fundamentals rather than fighting them. Every available timeframe forecasts up and to the right, and importantly the forecast magnitude *increases* with horizon: 4h fc_short/mid/long = 52.43/69.74/77.30, 1d = 20.62/51.90/72.69, 1wk = 13.62/41.37/60.58. That's textbook multi-timeframe agreement with mid/long forecasts of +60–77% — not a single-bar outlier. Crucially, you're not chasing. pos_in_21bar_range_pct is 0 / 0 / 6.01 across 4h/1d/1wk with drawdowns of -11.68% / -12.16% / -34.00% from recent highs. bullish_prob is 1.0 and near_term_bullish is 0.8. So you're buying a healthcare quality-compounder at the bottom of its 21-bar range, with the model expecting reversion higher — the exact opposite of the FUTU/Z/JBI/NOW setups where price is pinned at 100% of range and forecasts are stalling. News is a non-event, which is what you want. The three headlines are a Q2 earnings preview, a generic 'healthcare stocks to target' piece, and a ChartMill bull note calling it 'a Quality Affordable Growth Stock with Strong Earnings Momentum.' There's no guidance cut (unlike SRAD, which cut 2026 outlook and got PT-slashed), no legal overhang (unlike FUTU's DOJ probe), no dilution, no short-seller report. Compare to ALNY where Truist just lowered its PT, or TMUS where SpaceX headlines are actively pressuring the stock. Why today vs. wait: the Q2 print is imminent (~7/22 dated preview), and PODD is at 0% of its 21-bar range with a -34% weekly drawdown already priced in. You either buy pre-print with a defined stop, or you risk paying materially higher on a beat. Given the fundamentals-plus-tape combo is stronger here than in any other candidate, the asymmetry favors initiating now.

PODD forecast chart
Entry zone
$148–$152 (current $149.88); scale in a second tranche on a dip to $142–$145
Stop loss
$129 (below the weekly range low; risk ~14%)
First target
$180 (aligned with 4h fc_short +20% and 1d fc_short zone)
Longer target
$220–$240 (1d/1wk fc_long of +60–72% and analyst upside 39.3%)
Risks
  • Q2 2026 earnings on/near 7/22 preview date — a guide-down could immediately break the setup and take out the $129 stop
  • Perf 1Y is -42.03% and PerfYtd -41.31%, so momentum is still downtrend; a fresh leg lower is not off the table until price reclaims the 21-bar mid
  • Healthcare device competition (Tandem, Medtronic 780G) — any share-loss headline could re-rate the multiple lower than fwdPE 20.71
  • Short float 6.74% is moderate but adds volatility around the print
  • Institutional ownership is 103.97% (heavily crowded long) — a coordinated de-grossing event could exaggerate downside
Honorable mentions
TIGRCheapest growth on the list (fwdPE 6.11, PEG n/a but epsNextY 63.97%, salesYoY 48.35%, operMargin 45.3%). All three timeframes forecast up (4h +57/67/68, 1d +15/79/64, 1wk +0.6/49/65) with near_term_bullish 1.0 and 1wk pos_in_range only 14.97%. CNBC top-fintech recognition is a positive tailwind. Held back from #1 only by China-ADR overhang and smaller $867M cap.
WINGDeeply oversold (RSI 29.98, 1wk DD -37.61%, pos_in_range 0) with strong reversion forecasts (1d fc_mid +86.69%, fc_long +84.05%; 1wk fc_long +66.28%) and near_term_bullish 1.0. Fundamentals decent (operMargin 28.77%, profitMargin 16.15%) but fundamental_score only 6 and the recent Q2 flagged 'urban market challenges' — better as a BUY_PULLBACK / dead-cat bounce trade than a full-conviction hold.
Full ranking (31)
#SymbolVerdictScoreRead
1PODDBUY NOW9.1Fund score 8 + all-timeframe up forecasts (+60–77% long) + pos_in_range 0/0/6 + clean news = highest-conviction setup.
2TIGRBUY NOW8.5fwdPE 6.11 with 63.97% EPS growth, all-timeframe bullish forecasts, near_term_bullish 1.0, 1wk range only 14.97%.
3ALNYBUY NOW7.6ROE 100.7%, PEG 0.29, salesYoY 95.14%, 4h/1d forecasts +52–75% and RSI 30.97 oversold — Truist PT cut is a minor drag.
4MLCOBUY NOW7.4PE 9.57 / fwdPE 8.11 / PEG 0.35 with mid/long forecasts of +12–41% and mid-range positioning; 'worst is behind us' narrative building.
5WINGBUY PULLBACK7.2Deeply oversold (RSI 29.98, DD -37.61%) with fc_mid +86.69% but fundamental_score only 6 and Q2 flagged urban headwinds.
6CELHBUY PULLBACK7.0salesYoY 123.34%, near_term_bullish 0.8, 1d fc_mid +51.07%; short float 21.21% adds squeeze potential but 1h at 100% of range.
7AHCOBUY PULLBACK6.7RSI 20.66 washout with fc_short/mid/long of +52/52/52% on 4h; negative profitMargin -2.44% is the caveat.
8PODD_dup_placeholderAVOID0.0n/a
9MIRBUY PULLBACK6.64h/1d forecasts +34/28% and +28/38% but 1wk fc_long -14.25% caps upside; PT cuts from Citi/B. Riley.
10TMDXBUY PULLBACK6.4Great fundamentals (ROE 45.22%, profitMargin 27.04%) with 4h/1d fc_long +85/53%, but stock already +171% and 1wk DD -36.32%.
11ORCLWAIT6.3Solid fundamentals (ROE 54.28%, PEG 0.5) but 1wk forecasts all negative (-0.49/-8.65/-6.77) and pos_in_range 91–92% on 4h/1d = chasing.
12FBRTBUY PULLBACK6.1fwdPE 6.54, forecasts +23/20/19% on 4h and +5/17/18% on 1d, but modest weekly upside.
13PFSIBUY PULLBACK6.0fwdPE 7.05 with epsNextY 102.69%, 4h fc_long +50.76%, but PT recently cut 13.64% and analyst calls it 'risky value'.
14RBBNBUY PULLBACK5.9Recom 1.0 and fc_long +56% on 1wk but salesYoY -7.62% and operMargin -1.5% — earnings-growth story unproven.
15ONONWAIT5.8Quality growth (salesYoY 36%, profitMargin 8.16%) but pos_in_range 80–100% and earnings next week — wait for the print.
16BIRKBUY PULLBACK5.6Cheap luxury (fwdPE 13.46, profitMargin 16.26%) and RSI 32.99 but near_term_bullish only 0.2 and short-horizon forecasts negative.
17SPOTWAIT5.4300M subs milestone is real but pos_in_range 100% on 1d, 1wk fc_long -17.93% — chasing after positive print.
18CALXWAIT5.3PEG 0.48 and 1d fc_mid +32% but 1wk fc_short -6.2% and near_term_bullish only 0.4.
19AMSCWAIT5.1Great fundamentals (recom 1.0, ROE 35.56%) but 1wk fc_long -52.24% and just dropped -20% on a contract announcement — trend deteriorating.
20GOTUWAIT5.0epsNextY 1145% is optically insane but profitMargin -6.41% and micro-cap $220M — pure speculation.
21SDAWAIT4.8Recom 1.0 and BTIG buy but $80M micro-cap, PE 435, weekly forecasts of +672–884% look like model noise.
22JBIWAIT4.6All three timeframes pinned at pos_in_range 100 = fully extended; salesYoY -2.54%.
23NRGWAIT4.41wk fc_long -35.20% and 4h/1d oversold rebound only; profitMargin 0.53% is thin.
24VSTWAIT4.3Solid ROE 43% but 1wk fc_long -34.32% and salesYoY -24.36% — utilities weakness confirmed.
25NOWWAIT4.2Cybersecurity narrative strong but 1h/4h/1wk forecasts negative and pos_in_range 100% on three timeframes.
26PARAVOID4.1profitMargin -16.04%, ROE -9.09%, short float 25.13%, ballistic forecasts unreliable at 1d fc_long +112%.
27ZAVOID4.0PE 144, 500 layoffs just announced, pos_in_range 97–99% on 4h/1d — chasing into bad news.
28FUTUAVOID3.8DOJ probe and Hong Kong SFC asset freeze ($125M) headlines are landmines despite pretty fundamentals.
29TMUSAVOID3.6SpaceX mobile threat headlines are actively re-rating the sector lower; 1wk fc_short/mid negative.
30SEAVOID3.4bullish_prob only 0.4, pos_in_range 100% on 1d/1wk, TD Cowen Hold with PT cut.
31SRADAVOID2.8Cut 2026 outlook, down -16.7% on Q2, PT cuts from JPM and Truist — thesis is broken.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.